Effect of magnesium oxide supplementation on the gene expression associated with insulin, lipid and inflammatory metabolism in diabetic hemodialysis patients
Phase 3
- Conditions
- Hemodialysis.End stage renal diseaseN18.6
- Registration Number
- IRCT20190912044757N1
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
?Diabetic Hemodialysis patients with glomerular filtration less than 10 or less than 25 ml / min with malnutrition or hyperkalemia
Age 45-75 years
No smoking
Moderate hypertension (systolic blood pressure between 160-140 mmHg and diastolic blood pressure between 90-100 mmHg)
Exclusion Criteria
Unwillingness to participate in the study
Hypothyroidism or hyperthyroidism (clinical evaluation by a specialist physician and laboratory test)
Specific illness that may lead to hospitalization
High blood pressure (systolic pressure above 160 and diastolic pressure above 100 mm Hg)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expressed levels of proliferator-activated receptor gamma (PPAR-?) gene. Timepoint: At the beginning of the study (before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.
- Secondary Outcome Measures
Name Time Method